Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2023-02-07 Capital/Financing Update
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a letter from ThinkEquity LLC to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It references securities law rules (Rule 461, Rule 460, Rule 15c2-8) and discusses distribution of a preliminary prospectus. The content is related to the registration and offering process of securities, specifically a request for acceleration of the effective date of a registration statement, which is a capital raising activity. The document is short (1952 characters) and is a formal communication rather than a financial report or detailed filing. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-02-07 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter from MAIA Biotechnology, Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. This is a regulatory communication related to securities registration and does not contain financial statements, management discussion, or other report content. The document length is short (1281 characters) and is a formal request rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-02-07 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a detailed preliminary prospectus for a public offering of common stock by MAIA Biotechnology, Inc. The text includes extensive information about the company, its business, lead product candidate, regulatory strategy, risk factors, and underwriting details. Form S-1 is a registration statement used for initial public offerings (IPOs) or other securities offerings and is not a financial report like an annual or quarterly report. It is a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-02-06 English
10-Q/A
Interim / Quarterly Report 9M 2022
2023-02-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 3, 2023, by MAIA Biotechnology, Inc. It discusses the company's restatement of previously issued unaudited condensed consolidated financial statements from a prior quarterly report (Form 10-Q) due to accounting errors. The report also mentions the audit committee's conclusion and internal control weaknesses. The content focuses on audit-related matters and restatement of financials but is not a full audit report or annual report itself. It is a regulatory filing to inform the market of these material changes and internal control issues. Therefore, the document fits best under Regulatory Filings (RNS) as it is a current report disclosing material events and restatements, not the full audit report or quarterly report itself.
2023-02-06 English
PRIMARY DOCUMENT
Director's Dealing
2023-01-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.